Recent Quotes (30 days)

You have no recent quotes
chg | %

GeneNews Limited  

(Public, TSE:GEN)   Watch this stock  
Find more results for GEN
0.950
+0.030 (3.26%)
Delayed:   10:19AM EDT
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.95 - 0.95
52 week 0.39 - 1.08
Open 0.95
Vol / Avg. 7,654.00/26,496.00
Mkt cap 18.39M
P/E     -
Div/yield     -
EPS -0.32
Shares 19.35M
Beta 2.03
Inst. own     -

Key stats and ratios

Q3 (Sep '12) 2011
Net profit margin -905.24% -4445.15%
Operating margin -905.24% -4445.15%
EBITD margin - -3175.86%
Return on average assets -144.51% -98.10%
Return on average equity - -
Employees 17 -
Carbon Disclosure Rating - -

Address

Building 2, 2 East Beaver Creek Road
RICHMOND HILL, ON L4B 2N3
Canada
+1-905-7392030 (Phone)
+1-905-7392031 (Fax)

Website links

External links

Discussion Group - Google Finance

Description

GeneNews Limited (GeneNews) is a molecular diagnostics company. The Company is focused on the application of functional genomics to enable early diagnosis and personalized health management. The Company�s Sentinel Principle detects and stages virtually any disease or medical condition from a simple blood sample. GeneNews is applies the Sentinel Principle in areas with unmet clinical needs such as cancer, arthritis, cardiovascular disease and neurological disorders. Its ColonSentry product is used to determine an individual�s risk for colorectal cancer. During the year ended December 31, 2011, the Company announced the launch of ColonSentry in Malaysia. On February 21, 2012, the Company announced that its United States marketing partner, Enzo Clinical Labs Inc, had received clearance from the New York State Department of Health to perform, market and sell the ColonSentry test as a clinical laboratory service.

Officers and directors

Rory B. Riggs Independent Chairman of the Board
Gailina J. Liew President, Chief Operating Officer, General Counsel, Corporate Secretary, Director
Heiner Dreismann Ph.D. Interim Chief Executive Officer, Lead Director
Age: 59
Leslie Auld Chief Financial Officer, Treasurer
Karl Wassmann Executive Vice President - US Corporate Development
Harry A. Glorikian Independent Director
James R. Howard-Tripp Independent Director
Garth A. C. MacRae Independent Director
David B. Sable M.D. Independent Director